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INTRODUCTION 1
Blood lipid abnormalities are a frequent hallmark of active rheumatoid arthritis (RA). Many 2 authors have reported an alteration of the lipid profile in RA patients, especially those of 3 lipoproteins during high disease activity states [1] [2] [3] . Accordingly, disease activity control by 4 different immunomodulatory treatment strategies is related to a restoration of the lipid profile to 5 different degrees, although certain controversy exists 1 . Due to the fluctuation of some 6 lipoproteins in the context of a chronic inflammation, and taking into account that a single lipid 7 compound cannot provide enough information on its own, there is a need for more reliable 8 biomarkers related to the lipid profile in RA. 9
The classical clinical management of blood lipids focused on lipoproteins is currently 10 challenged by a compelling body of evidence highlighting an important contribution of other 11 lipid compounds, such as triglycerides (TG), lipoprotein A or cholesterol remnants [4] [5] [6] . Different 12 panels of experts have raised the point that individual lipoproteins alone may not be accurate for 13 patient stratification and treatment recommendations in the clinical setting (reviewed in 5 ). 14 Actually, reducing LDL-cholesterol (LDL-c) levels as a therapeutic target is now put into 15 question and there is a recommendation to consider other lipid fractions or surrogate markers as 16 they can be more informative 7 . TG exhibit important differences compared to lipoproteins in 17 their origin, metabolic pathways and downstream effects in different cell types. Therefore, it is 18 tempting to speculate that their inclusion in the clinical management will bring valuable 19 information which can complement that of provided by lipoproteins. In fact, several 20 epidemiological studies have found an attenuation of the protective effect of HDL-cholesterol 21 (HDL-c) levels on cardiovascular disease (CVD) outcomes when adjusted for TG [8] [9] [10] , thus 22 suggesting the existence of interactive effects among lipid classes. Hence, there is a growing 23 body of evidence supporting the study of combined indices, especially when TG are included 11 . 24
Consequently, in recent years the relevance of a lipid profile characterized by decreased HDL-c 25 levels and elevated TG has emerged 5 . This profile has been linked to inflammation and 26 atherosclerosis development, although some knowledge gaps remain 4 . Recently, this profile has 27 been shown to affect the leukocyte gene expression in dyslipidemia subjects 12 . However, the 28 clinical and immunological relevance of this profile in RA is unknown. 29
On the other hand, current epidemiological and experimental studies have stated that the only 30 analysis of lipid levels is a too simplistic approach that does not reflect lipoprotein functionality. 31
Lipoproteins can develop a broad range of enzymatic activities, apart from cholesterol transport 32 13 . Interestingly, lipoprotein functionality seems to have a better clinical relevance than levels 33 14, 15 . Among lipoprotein functions, anti-oxidant properties are emerging as a pivotal player to 34 understand the interaction between lipid profiles and inflammation 16 , compromised anti-oxidant 35 guidelines 19 . Exclusion criteria was the previous diagnosis of any immune-mediated condition. 18
Exclusion criteria for all study groups were: recent (<3 months) infections or surgeries, cancer 19 diagnosis or pregnancy. 20
Automated serum lipids analysis was performed on all the participants in fresh blood samples 21 after an overnight fast. TRL levels were calculated according to the equation provided by 22
Hermans et al. 20 . Serum samples were stored at -80ºC until laboratory measurements were 23 carried out. Approval for the study was obtained from the Institutional Review Board (Comité 24 de Ética Regional de Investigación Clínica), in compliance with the Declaration of Helsinki. All 25 the participants gave written informed consent prior to their inclusion in the study. 26
Quantification of inflammatory mediators' serum levels 27
TNFα, MCP-1, sICAM-1, EGF, IP-10, leptin and resistin serum levels were measured by means 28 of a Mini ELISA Development Kits (PeproTech), following the instructions provided by the 29 manufacturer (detection limits were: 3.9 pg/ml, 8 pg/ml, 23.4 pg/ml, 3.9 pg/ml, 3.8 pg/ml, 63 30 pg/ml and 24 pg/ml, respectively). IFNγ serum levels were quantified using an OptEIA kit (BD) 31 following the manufacturer's protocol (detection limit: 0.58 pg/ml). 32 M A N U S C R I P T
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Levels of IL-8 and GM-CSF were quantified using a Cytometric Bead Array Flex Set (BD) in a 1 FACS Canto II flow cytometer using FCAP Array v.1.0.1, following the manufacturer's 2 instructions. The detection limits were 1.2 pg/ml and 0.2 pg/ml, respectively. 3
Assessment of PON1 activity 4
PON1 activity was measured in serum samples using paraoxon (Sigma Aldrich, Germany) as 5 substrate, as previously described 21 . PON1 activity was expressed as units (U), where one U 6 represent the micromoles of p-nitrophenol formed per minute and per ml of serum. 7
Analysis of Total Antioxidant Capacity 8
A spectrophotometric method based on the cupric reducing antioxidant capacity (CUPRAC 9 method) using a commercial kit (TAC Assay Kit, Sciencell Research Laboratories) was used to 10 quantify the Total Antioxidant Capacity of serum samples. Serum TAC was expressed as mM 11
Trolox equivalent units (mM T-Eq). 12
Analysis of Free Fatty Acids 13
The levels of total Free Fatty Acids (FFA) were quantified in serum samples using an 14 enzymatic, colorimetric assay using a commercial kit (NEFA kit, Roche) according to the 15 protocol provided by the manufacturer. The detection limit was 0.02 mM. 16
PON1 rs662 genotyping 17
DNA was isolated from peripheral blood using conventional methods. The PON1 rs662 18 polymorphism was genotyped with TaqMan predesigned single-nucleotide polymorphism 19 (SNP) genotyping assays (C___2548962_20) in a 7900 HT Real-Time polymerase chain 20 reaction (PCR) system, as previously described 21 . 21
Statistical analyses 22
Continuous variables were expressed as median (interquartile range) or mean ± standard 23 deviation, whereas n(%) was used for categorical ones. Differences among groups were 24 analyzed by Mann Withney U, Kruskal-Wallis (with Dunn-Bonferroni correction for multiple 25 comparisons), χ2 or Fisher exact tests, as appropriate. Wilcoxon test was used for paired 26 samples. Correlations were assessed by Spearman ranks test. The association of categorical 27 variables adjusted for confounders was analyzed by multivariate logistic regression models, and 28 odds ratios (OR) with 95% confidence intervals (CI) were computed. When required, variables 29
were log-transformed to achieve a normal distribution. With an α=0.05, and assuming a 30 Given the controversy on the blood lipid levels and their functionality in RA, and taking into 3 account the heterogeneity among lipid classes, we decided to evaluate the impact of a combined 4 altered lipid profile in RA. To this aim, we focused on the simultaneous presence of decreased 5 HDL-c levels and elevated triglycerides (TG high HDL low ) by evaluating this combined profile in 6 113 RA patients, 27 non-autoimmune dyslipidemic patients and 113 age-and gender-matched 7 HC. No differences in the lipid profile between HC and RA patients were observed. The cut-off 8 points for the combined lipid profile were obtained from the HC group 12 . Thus, by splitting the 9 HC group into tertiles, 102 mg/dl (upper tertile) and 52 mg/dl (lower tertile) were established as 10 high triglycerides and low HDL-c cut-offs, respectively. Of note, when these cut-offs were 11 applied to patients and controls, no significant differences in the prevalence of the TG high HDL low 12 profile were observed among groups ( In addition to their levels, a growing body of evidence highlights the relevance of HDL 19 functionality. Due to the significance of the PON1 rs662 genetic variants on the HDL-PON1 20 antioxidant activity, we further examined whether the presence of the TG high HDL low profile in 21 RA patients could have a different effect depending on the rs662 status. 22
As expected, a gene-dosage effect was observed on serum PON1 activity, patients harboring the 23 QQ genotype exhibiting the lowest levels (Supplementary Figure 1A) . However, the prevalence 24 (Table 4) . Moreover, TRL were correlated with TNFα (r=0.340, p=0.071) and 31 MCP-1 (r=0.604, p<0.001) levels in QQ-patients but not in those QR or RR. The altered lipid 32 profile did not influence the FFA levels in any of the rs662 variants (QQ: p=0.318, QR: p=0.538 33 and RR: p=0.864). Equivalent results were obtained for PON1 activity and TAC (Table 4) .
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Overall, these findings revealed a link between the TG high HDL low lipid profile and inflammation 1 in RA, a rs662-driven effect regulating these associations. Moreover, a decreased antioxidant 2 milieu as a consequence of the QQ rs662 status, but not an increased release of FFA, seem to 3 underlie this effect. TNFα-blockade has been reported to be able to down-regulate several inflammatory mediators 6 as well as to impact the lipid profile in RA patients. The negative association observed between 7
anti-TNFα treatment and the TG high HDL low profile ( of the TNFα-blockade on inflammatory mediators, lipid profile and PON1 activity in a group of 13 RA patients prospectively followed for three months. 14 None of the patients who achieved an EULAR good clinical response exhibited the 15 TG high HDL low profile (Table 5) , whereas it was present in 6 patients within the non-responder 16 group (p=0.021). Similarly, TNFα-blockade was associated with decreasing serum levels of 17
TNFα and MCP-1 in responders, but not in their non-responder counterparts. TNFα-blockade 18 had no effect on serum FFA levels (p=0.221), whereas a slight increase in serum PON1 activity 
The links between the altered blood lipid profile and inflammation in RA are still poorly 2 understood. Although several studies have focused on individual lipid classes, less attention has 3 been paid to combined lipid approaches, lipoprotein functionality as well as their impact on 4 surrounding mediators. In the present study, we show the presence of a combined lipid profile in 5 RA, characterized by altered levels of TG and HDL-c and related to the TRL levels. Although 6 no differences in prevalence compared to HC were detected, this profile was associated with 7 systemic inflammation and a poor clinical response upon TNFα-blockade. A decreased 8 antioxidant status seems to underlie these effects. Overall, these findings emphasize the 9 relevance of the HDL dysfunction in RA. 10
Most of studies on lipid profiles in RA were focused on lipoprotein levels, whereas the role of 11 TG, and its clinical relevance beyond lipid metabolism, in RA have been ill-defined. As in other 12 conditions, the use of lipid ratios has started to become used in RA. The EULAR consensus for 13 cardiovascular risk management in inflammatory arthritis encourages the use of the total-to 14 HDL-c ratio 22 . However, several concerns need to be underlined. On the one hand, this lipid 15 ratio still underestimates the use of TG levels, as they are not included. However, important 16 divergences in the association between TG and inflammatory markers compared to lipoproteins 17 or cholesterol composite indices arise in RA 23 . On the other hand, lipid ratios imply, at least in 18 part, certain stoichiometry between the lipid classes considered. Although this may not be a 19 problem when similar species (for instance, lipoproteins) are studied, this approach may yield 20 inconclusive results when different compounds are analyzed. This may account for the lack of 21 appropriate results when the TG/HDL ratio was studied in other conditions. Similarly, since 22 non-linear associations between blood lipids and clinical outcomes have been reported in RA 1 , 23 simple ratios could not be adequate. It is important to note that interesting findings arise even 24 within normal ranges of individual lipid classes, thus strengthening the relevance of the study of 25 the combined profile and the need for different cut-offs than those used for single lipid classes 26 alone. Therefore, a different combined approach as the one herein reported may provide more 27 reliable results. 28
Our findings revealed an association between the TG high HDL low profile with elevated TRL, thus 29 supporting the deleterious effect of this combined profile. High TG and TRL levels can impact 30 the HDL-c levels, composition and thus, functional status. Elevated TG and TRL may lead to a 31 greater cholesteryl ester exchange via Cholesteryl Ester Transfer Protein (CETP) between TRL 32 and nascent HDL, resulting in TG-rich small, dense HDL particles with reduced anti-oxidant 33 and anti-inflammatory activities and decreased cholesterol-accepting properties 24, 25 . 34
Importantly, increased CETP has been reported in RA 26 . Under these circumstances, LDL 35 M A N U S C R I P T
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hepatic metabolism turns these lipoproteins into smaller and denser particles, with reduced 1 avidity for their liver receptors. Then, these particles exhibit a longer half-life and are more 2 susceptible to oxidization and to subsequent monocyte/macrophages uptake 4,27 . Interestingly, it 3 has been demonstrated that HDL particles from individuals with low HDL-c and high TG levels 4 exhibit a reduced capacity to promote cholesterol efflux (CE) 14 . Decreased CE has been also 5 found in RA patients linked to disease activity 28 , and being partially restored upon TNFα-6 blockade 29-31 , although certain controversy exists 32 . These lines of evidence align with the 7 decreased prevalence of the TG high HDL low profile in RA patients undergoing anti-TNFα 8 treatment found in our study. Moreover, these results may suggest certain degree of causality of 9 the TNFα pathway in the altered lipid profile in RA. The fact that an effective TNFα blockade 10 was associated with a normal lipid profile, whereas the lack of a beneficial effect related to the 11 presence of this altered profile, is also in accordance with this hypothesis. Although our findings 12 may suggest the use of the TG high HDL low profile as a biomarker of therapy response, the low 13 sample size of our study is an important limitation. Larger and long-term clinical studies are 14
needed. 15
The altered CE may account, at least in part, for the associations between the altered lipid 16 profile and the inflammatory burden. CE by HDL can reduce the raft-like regions in the 17 A key result from our study is the interaction between the lipid profile and the oxidative status. 26
The clinical relevance of the TG high HDL low profile was not uniform among individuals, but it 27 seemed to be dependent on the oxidative status. Thus, a profound effect on the inflammatory 28 burden was observed in RA, where PON1 activity and TAC were strongly diminished, but not 29 in HC or DL groups. This notion is strengthened by the association with the PON1 rs662 30 genetic variants. Among RA patients, only in those with the lowest PON1-mediated antioxidant 31 activity (that is, those harboring the QQ status) showed that association. Therefore, these results 32 disclose a link between the altered lipid profile and the oxidant status, which are reinforced by 33 the negative association between TRL levels and PON1 activity. In this sense, it is important to 34 note that the impaired CE in RA has been related to decreased PON1 functionality and 35 increased MPO activity 28 . A causative role of MPO in the HDL dysfunction has been also 36 M A N U S C R I P T A C C E P T E D 
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Our findings provide valuable insight for the clinical setting and personalized medicine. 1
Although lipid ratios are recommended in the clinical management of RA, its current use may 2 be revised and additional biomarkers are needed. Moreover, whether lipoprotein ratios can 3 provide information on the functional status of HDL is unknown. Taking into account the 4 relevance of a disturbed lipoprotein functionality 4,14,15 , it may be advisable to include this 5 pathological finding in the clinical setting. However, routine analyses for HDL functional status 6 are lacking, due to its time and methodological limitations. Taking into account our findings, the 7 TG high HDL low profile can be considered as a surrogate biomarker of an altered HDL functional 8 status. Thus, our results provide a new rationale for patient stratification and treatment decision 9 in this sense, as the TG high HDL low profile can be used to identify RA patients with an enhanced 10 systemic response and increased pro-oxidative status, linked to HDL dysfunction. These 11 patients may be considered for anti-TNFα treatment and/or some therapeutic drugs able to 12 counteract oxidative stress linked to inflammation 52 . 13
In conclusion, our results revealed that the TG high HDL low lipid profile in RA patients is 14 associated with a number of inflammatory mediators and negatively related to anti-TNFα 15 therapy usage. More importantly, the effect of this profile seems to be related to a decreased 16 antioxidant activity, a negative link between TRL and PON1 activity being observed. Finally, a 17 good clinical outcome upon TNFα-blockade was associated with prevention of this altered 18 profile. To the best of our knowledge, this is the first study emphasizing the relevance of this 19 lipid profile in RA patients and addressing a comprehensive analysis of the altered lipid profile, 20 oxidative status, inflammation and genetic determinants of HDL-PON1 functionality. 21
22
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